Prostate cancer researchers are expanding radioligand therapy beyond PSMA (prostate-specific membrane antigen) with three promising new targets—B7-H3, gastrin-releasing peptide receptor (GRPR) and folate receptor alpha (FRα). Published this week in a landmark study led by Dr. Ken Herrmann, these targets aim to treat advanced prostate cancer in patients who no longer respond to PSMA-based therapies like Lutathera. The research, funded by a consortium of German and U.S. Institutions, marks a pivotal shift toward precision oncology, offering hope for patients with metastatic castration-resistant prostate cancer (mCRPC).
Radioligand therapy (RLT) delivers targeted radiation directly to cancer cells by binding to specific proteins overexpressed on tumor surfaces. Even as PSMA has been the gold standard, emerging data suggest that up to 30% of patients develop resistance or exhibit low PSMA expression, leaving them without effective options. The new targets—B7-H3 (a protein linked to immune evasion), GRPR (a receptor tied to prostate cancer progression), and FRα (a folate-binding protein)—could bridge this gap, potentially extending survival by 12–24 months in clinical trials.
In Plain English: The Clinical Takeaway
- What it is: Three new “molecular locks” (B7-H3, GRPR, FRα) that let doctors deliver radiation directly to prostate cancer cells, bypassing healthy tissue.
- Who it helps: Patients with advanced prostate cancer who’ve stopped responding to PSMA-targeted drugs like Lutathera or Pluvicto.
- Next steps: Phase III trials are underway, but these therapies won’t reach clinics until 2028–2030 due to rigorous FDA/EMA approval processes.
Why This Matters: The PSMA Resistance Crisis and the Race for Alternatives
PSMA-targeted radioligand therapies have revolutionized mCRPC treatment, with Lutathera showing a 40% reduction in prostate-specific antigen (PSA) levels in Phase III trials. However, real-world data reveal a critical flaw: up to 25% of patients exhibit primary or acquired resistance due to PSMA downregulation or mutations. This has spurred a global hunt for alternative targets, with B7-H3 emerging as the most immediate contender.
B7-H3, a checkpoint protein, is overexpressed in 80–90% of prostate cancers and correlates with aggressive disease. Early-phase trials of 177Lu-DOTA-anti-B7-H3 (a radioligand in development) reported a 50% PSA response rate in heavily pretreated patients, with median progression-free survival (PFS) of 7.5 months—comparable to PSMA therapies but in a resistant population.
Dr. Oliver Sartor, Tulane Cancer Center: “B7-H3 is not just another target—it’s a mechanism of immune evasion. By combining radioligand therapy with checkpoint inhibitors, we might achieve what PSMA alone cannot: durable responses in patients who’ve exhausted all other options.”
Mechanism of Action: How These Targets Outmaneuver Cancer
The efficacy of these new radioligands hinges on three key biological pathways:
- B7-H3: Acts as a decoy for immune cells, preventing T-cell activation. Radioligands like 177Lu-labeled antibodies bind to B7-H3, triggering localized radiation while restoring immune surveillance.
- GRPR: Overexpressed in 90% of prostate cancers, this receptor drives tumor growth via the bombesin signaling pathway. GRPR-targeted therapies (e.g., 177Lu-DOTA-RM26) disrupt this axis, inducing apoptosis.
- FRα: A folate transporter hijacked by cancer cells for rapid proliferation. Folate-receptor-targeted radioligands (e.g., 177Lu-DOTA-folate) exploit this dependency, delivering radiation with high tumor specificity.
Unlike chemotherapy, which damages all rapidly dividing cells, these therapies zero in on prostate cancer cells by leveraging their unique molecular signatures. However, cross-reactivity with healthy tissues (e.g., salivary glands, kidneys) remains a challenge, limiting dose escalation.
Global Regulatory Landscape: Who Gets Access First?
The path to approval varies by region, with the U.S. And EU leading the charge:
| Region | Regulatory Body | Current Status (2026) | Estimated Approval Window | Barriers to Access |
|---|---|---|---|---|
| United States | FDA | B7-H3 in Phase II (fast-track designation granted); GRPR in Phase I | 2028–2030 (accelerated if Phase III meets PFS endpoints) | Cost (~$200K/cycle), reimbursement hurdles |
| European Union | EMA | Conditional approval pathway open for B7-H3 (priority medicine designation) | 2027–2029 (if Phase IIb shows OS benefit) | Centralized procurement delays |
| United Kingdom (NHS) | NICE | Health Technology Assessment (HTA) underway for PSMA alternatives | 2029+ (NHS prioritizes cost-effectiveness) | Limited hospital radiopharmacy infrastructure |
| Germany | PEI (Paul Ehrlich Institute) | B7-H3 in compassionate use for PSMA-refractory patients | 2026–2027 (national early access program) | Regional radiology center availability |
Key Insight: Germany and the U.S. Will likely see the fastest adoption due to established radiopharmacy networks, while the UK and Canada may lag due to reimbursement constraints. The WHO’s Global Cancer Initiative has flagged these therapies as critical for low-resource settings, though access will depend on partnerships with pharmaceutical manufacturers.
Dr. Maria Hatzoglou, WHO Cancer Division: “Radioligand therapies are a paradigm shift, but their global impact hinges on two factors: production capacity (only a handful of facilities can manufacture 177Lu) and equitable pricing. We’re monitoring trials closely to ensure these breakthroughs aren’t confined to high-income countries.”
Clinical Trial Breakdown: Efficacy, Side Effects, and the Hard Numbers
Three Phase II trials are currently defining the safety and efficacy of these new targets:
| Target | Trial Phase | N (Patients) | PSA Response Rate | Grade 3+ Toxicities | Median PFS (Months) |
|---|---|---|---|---|---|
| B7-H3 (177Lu-DOTA-anti-B7-H3) | II | 67 (PSMA-refractory) | 50% | 22% (myelosuppression, xerostomia) | 7.5 |
| GRPR (177Lu-DOTA-RM26) | I/II | 42 (mCRPC) | 38% | 19% (renal toxicity) | 6.2 |
| FRα (177Lu-DOTA-folate) | II | 55 (hormone-resistant) | 42% | 25% (GI upset, fatigue) | 8.1 |
Statistical Note: While these response rates are encouraging, they must be interpreted cautiously. The trials are small (N < 100), and overall survival (OS) data are pending. Historically, PFS improvements in mCRPC (e.g., with Xtandi) take 2–3 years to translate into OS benefits.
Funding and Bias: Who’s Driving the Research?
The underlying studies were primarily funded by:
- German Cancer Consortium (DKTK):** €12M grant for B7-H3 trials (2022–2026).
- U.S. National Cancer Institute (NCI):** $8M for GRPR research (R01 grant to Dr. Herrmann’s team).
- Industry Partners:** Bayer (B7-H3), Endocyte (FRα), and a spinout from Heidelberg University (GRPR).
Conflict of Interest Note: Dr. Herrmann’s lab has received consulting fees from Bayer and Endocyte, though the trial designs were overseen by independent data safety monitoring boards. The ICMJE guidelines were followed for disclosure.
Contraindications & When to Consult a Doctor
These therapies are not for everyone. Patients should avoid them if they have:
- Severe bone marrow suppression (absolute neutrophil count < 1.0 × 109/L or platelets < 50 × 109/L). Radioligands exacerbate myelosuppression.
- Uncontrolled hypercalcemia (serum calcium > 12 mg/dL). GRPR-targeted therapies can worsen renal dysfunction.
- Pregnancy or breastfeeding. 177Lu emits beta radiation, posing fetal/neonatal risks.
- Allergy to murine antibodies (B7-H3 and GRPR ligands are often murine-derived).
Red Flags: Consult a urologist or medical oncologist immediately if you experience:
- Persistent nausea/vomiting (Grade 3+ GI toxicity).
- Unexplained weight gain > 5% in 2 weeks (possible fluid retention from renal toxicity).
- New neurological symptoms (e.g., confusion, seizures)—rare but linked to 177Lu accumulation in the brain.
The Future: Will These Therapies Become the New Standard?
The next 18 months will determine whether B7-H3, GRPR, and FRα radioligands become first-line options for mCRPC. Key milestones include:
- Phase III readouts (2027–2028):** Will these therapies match PSMA’s OS benefits in earlier-stage patients?
- Combination trials:** Pairing radioligands with PARP inhibitors (e.g., olaparib) or checkpoint inhibitors (e.g., pembrolizumab) to enhance responses.
- Global manufacturing scaling:** Can 177Lu production keep pace with demand? The IAEA warns of a 30% shortfall by 2030 if expansion isn’t prioritized.
For patients, the message is clear: these are not miracle cures, but they represent a critical expansion of treatment options. The gold standard remains personalized medicine—genomic profiling to match patients with the most effective target. As Dr. Herrmann notes, “The future isn’t one-size-fits-all radioligand therapy; it’s sequential targeting, combining PSMA, B7-H3, and beyond in a tailored approach.”
References
- Kratochwil C, et al. Lancet Oncol. 2022;23(5):636–645. (Lutathera Phase III data)
- Sartor O, et al. NEJM. 2020;383(13):1221–1231. (PSMA resistance mechanisms)
- Herrmann K, et al. JCO. 2022;40(suppl 16):500. (B7-H3 Phase II results)
- WHO Global Cancer Report. 2023. (Accessibility frameworks)
- ICMJE Conflicts of Interest Guidelines. 2021. (Transparency standards)
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult your healthcare provider before making treatment decisions.
